Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Multiple sclerosis (MS) is more common in women than men and is most commonly
diagnosed in early adulthood; thus, many patients will not have completed their families at …

Multiple sclerosis is often diagnosed in patients who are planning on having children.
Although multiple sclerosis does not negatively influence most pregnancy outcomes, less is …

Background & Aims Exposure to biologic and immunosuppressant agents during
breastfeeding is controversial, and there are limited data on safety. We investigated whether …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Abstract Purpose of Review We review data available for treatment of multiple sclerosis (MS)
before, during, and after pregnancy. We present recent data on disease-modifying therapies …

Background Patients with multiple sclerosis (MS) or Crohn's disease (CD) being treated with
natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are …

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …

Objective To investigate pregnancy-related disease activity in a contemporary multiple
sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In
recent years, many disease-modifying therapies (DMT) have been approved for MS …